NPPES file of Aug 9, 2026

Thomas Langworthy Luzier, M.D.

Allergy & Immunology Physician · Aberdeen, SD

Thomas Langworthy Luzier, M.D. is an allergy & immunology physician with a practice address in Aberdeen, South Dakota, and NPI 1578595096, issued on Jul 7, 2006. Check the license (South Dakota SD1359, as entered in NPPES) on the South Dakota Board of Medical and Osteopathic Examiners; the Medicare figures below come from public CMS files.

Record from CMS NPPES, file of Aug 9, 2026 · Medicare files 2023 and 2024 · method · Verify with CMS →

NPPES recordNPPES file of Aug 9, 2026
1578595096
Name
Thomas Langworthy Luzier
Credential
M.D.
Primary taxonomy
Allergy & Immunology Physician 207K00000X
License number
SD1359 SD
Self-reported in NPPES; status is on the state search
Practice location
201 S Lloyd St Ste W110, Aberdeen, SD 57401
Phone
(605) 225-0025
Enumerated
Jul 7, 2006
Record last updated
May 8, 2023
Fax
(605) 225-2259
Medicaid IDs
15845 ND
59-00210 SD
Medicare enrollment
Enrolled (PECOS I20100630000847); accepts Medicare assignment
Medical or professional school
University Of Kansas School Of Med (Kc/Wich/Sal), 1974
Entity
Type 1 · individual
Public record from CMS NPPES (open it on the CMS NPI Registry). Enrollment, assignment, school and telehealth: CMS Doctors and Clinicians file, Aug 2026. A record is not a license: verify it with the state board.
Download card Updates feed

Verify Thomas Langworthy Luzier in five checks

  1. 1IdentityNPI record in CMS NPPESNPI lookupConfirmed in NPPES
  2. 2LicenseActive license and public ordersSouth Dakota Board of Medical and Osteopathic Examiners
    Search for license SD1359
    Check the board
  3. 3Other statesLicenses and actions elsewhereDocInfo (FSMB)Not checked
  4. 4ExclusionsMedicare and Medicaid bansHHS-OIG exclusion listNot checked
  5. 5CertificationBoard certificationABMS AOA NCCPA AANPNot checked
Open the South Dakota license search

PlainDoctor does not match the HHS-OIG exclusion list to individual records: most entries carry no NPI. Search the OIG exclusion list by name.

Is this page about you? You can ask us to correct, restrict or remove it: how.

2.8 times the Medicare Part D claims of the average allergy & immunology physician in 2024

2,083 Medicare Part D claims for 289 beneficiaries, against an average of 741 among the 2,899 providers of this specialty who prescribed in Part D. Brand-name drugs were 26% of claims.

  1. Thomas Luzier2,083
  2. Specialty average741

Most prescribed

  1. Montelukast Sodium324 claims
  2. Trelegy Ellipta132 claims
  3. Famotidine129 claims
  4. Prednisone122 claims
  5. Doxycycline Hyclate87 claims
  6. Omeprazole81 claims

Source: CMS Medicare Part D Prescribers by Provider and Drug, 2024 (data.cms.gov). Part D covers prescriptions for Medicare patients only; drugs with fewer than 11 claims are not published.

The MIPS final score for 2023 (Medicare payment program): 10.4 of 100

The Merit-based Incentive Payment System score is reported for this clinician. Four categories are weighted into the final score; the average among 454,083 clinicians with a measured score was 83.5.

  1. Qualityout of 100 · 30% of the final score0.0
  2. Costout of 100 · 30%34.5
  3. Promoting interoperabilitynot scored (reweighted)
  4. Improvement activities0 of 40 points · 15%0.0

Source: CMS Quality Payment Program, MIPS performance year 2023; category weights for 2023 (qpp.cms.gov).

Industry payments in 2024: $2,124.45

117 payments; by number, the most common kind was food and beverage; the largest payer was AstraZeneca Pharmaceuticals LP. The 2,496 providers of this specialty with any payment received $8,321.81 on average. Payments are reported by manufacturers, not by the provider, and are not a sign of wrongdoing.

  1. Thomas Luzier$2,124.45
  2. Specialty average$8,321.81

Source: CMS Open Payments, program year 2024 (openpaymentsdata.cms.gov); average among providers of this specialty with at least one payment.

Allergy & Immunology Physician providers in South Dakota

There are 3 allergy & immunology physician records in South Dakota.

Other allergy & immunology physician records in South Dakota

  1. Keerthi BansalSioux Falls, SD1053814863
  2. Jason Schend, D.O.Sioux Falls, SD1861833774

Common questions

What is Thomas Langworthy Luzier, M.D.'s NPI number?

Thomas Langworthy Luzier, M.D.'s National Provider Identifier (NPI) is 1578595096, issued on Jul 7, 2006. An NPI identifies a provider in billing; it is not a license.

Where is Thomas Langworthy Luzier, M.D. located?

The NPPES record lists a practice address at 201 S Lloyd St Ste W110, Aberdeen, SD, 57401. Phone: (605) 225-0025. Providers update this record themselves, so call before visiting.

How can I verify Thomas Langworthy Luzier, M.D.'s license?

NPPES lists South Dakota license number SD1359, as entered by the provider. Search the South Dakota Board of Medical and Osteopathic Examiners at https://www.sdbmoe.gov/. The NPPES record confirms identity only; the state search shows license status, expiration and public orders.

How much does Thomas Langworthy Luzier, M.D. prescribe under Medicare Part D?

In 2024, Thomas Langworthy Luzier, M.D. had 2,083 Medicare Part D claims for 289 beneficiaries; the average among allergy & immunology physician prescribers was 741. Part D covers Medicare prescriptions only.

What is Thomas Langworthy Luzier, M.D.'s MIPS final score?

The 2023 MIPS final score is 10.4 of 100. The average among 454,083 clinicians with a measured score was 83.5.

Source: CMS National Plan and Provider Enumeration System (NPPES), file of Aug 9, 2026 (NPPES files on CMS.gov); NUCC Health Care Provider Taxonomy. Medicare files from data.cms.gov. An NPI identifies who bills; it is not a license.

Figures on PlainDoctor are read from the federal files each page names (CMS NPPES, Medicare Part D, MIPS, Open Payments; the HHS-OIG exclusion list only as counts) and from Census population estimates, with the file date shown beside them. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of Aug 9, 2026.